INTRODUCING A WORLD FIRST: PATENTED PRESCRIPTIVE AI

July 2019



"Veriluma's value proposition is unlike that of any other vendor we have ever seen..."

GARTNER

Disclosure to investors

This presentation has been prepared by Veriluma A.C.N. 48 142 901 353 (VRI). The information contained in presentation this is not recommendation. This presentation is of a general nature and does not purport to be complete, nor does it contain all of the information which would be required in a prospectus prepared in accordance with the requirements of the Corporations 2001 Act (Cth) (Corporations Act). It contains summary information about Veriluma and its activities and should be read in conjunction with Veriluma's periodic other disclosure announcements to the ASX, which are available at asx.com.au

This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in Veriluma. These forward-looking statements are subject to risks, uncertainties and assumptions and other factors, many of which are beyond the control of Veriluma. Veriluma cautions that forward-looking statements are o f guarantees future not performance and its actual results of operations, financial condition, performance, prospects, growth or opportunities and the development to the industry in which Veriluma operates may differ materially from those made in, or suggested by, the forward-looking statements contained in this presentation.

In addition, Veriluma does guarantee any particular rate of return or the performance Veriluma, nor does it guarantee the repayment or maintenance of capital particular tax any or Investors should note treatment. that past performance may not be indicative o f results or developments in future periods and can not be relied upon as indicator of (and provides guidance as to) Veriluma's future performance.

The Veriluma objective

OBJECTIVE: \$5.4M CAP RAISE AT \$0.03 (3 CENTS)

ASX:VRI

At relist, post 10:1 consolidation:
 Shares on issue: 259,300,614

Options on issue:
 2,000,000 at \$0.03 before 4 April 2022

35,000,000 at \$0.04 before 30 June 2022

35,000,000 at \$0.08 before 30 June 2023

Performance shares on issue:

13,000,000 various classes with revenue or VWAP milestones

MARKET CAP

\$7.779M

CASH AT RELIST

\$4.381M

The Veriluma Executive

ANDREW GROVER

Executive Chairman

Andrew's focus is on innovative businesses. As a former CEO, Andrew facilitated the merger of his executive recruitment agency with an ASX listed company. He has been featured in BRW Fast 100 and Deloitte's Fast 50. Today, Andrew spends his energies on technology and invests in both listed and private equity ventures.

STEVE FORMICA

Non Executive Director

Experienced NED of ASX listed companies with his professional and practical experience in building, construction and mining industries.

ELIZABETH WHITELOCK

Managing Director and founding shareholder

Elizabeth is an executive skilled in managing large teams for global tech, including roles at IBM and SAS. Skilled in software development for products delivering CRM, SAAS and Professional Services, Elizabeth has a singular focus to grow the Veriluma team in global expansion.

ARUN SENGUPTA

Non Executive Director

Experience in financial markets, corporate finance and private equity and has been involved in the establishment, capital raising and operation of ASX listed companies.

We are Veriluma. Prescriptive Al.

GLOBAL

Veriluma is an Australian founded software company working in the area of prescriptive AI all around the world.

AI SOFTWARE

We predict outcomes. With certainty. With absolute transparency. We work with our clients to deliver:

- bespoke solutions
- go-to-market applications
- consulting led insight

PATENTED

Veriluma's prescriptive
AI is a patented, analytical
engine that combines data
and human subjectivity to
solve problems quickly
with great accuracy and
without bias.

ADAPTIVE

As the world changes, the inclusion of new variables and data creates complexity and typically wastes time. With Veriluma, these are simple inputs. Done fast.













VERILUMA
PRESCRIPTIVE AI

PROBLEM IN

HUMAN CONCEPTS ADDED SOLUTIONS REACHED

PROBLEM SOLVED

Why Veriluma AI?

"VERILUMA IS
ENGINEERED TO FIND
THE BEST COURSE OF
ACTION FOR ANY
GIVEN SITUATION"

PROBLEM SOLVED

CLARITY

where a significant amount of conflicting information exists

TRANSPARENCY

risks and opportunities are identified with a date and time stamped audit trail

SPEED & PREDICTABILITY

prescriptive analytics with an ability to problem solve instantly and in real time

CERTAINTY

sound, logical algorithmic base for reasoning

SIMPLICITY

simple to deploy and integrate with exiting systems: visual workflow software interface


"Artificial intelligence is the future, not only for Russia, but for all humankind..."

VLADIMIR PUTIN

Veriluma AI and the global market potential

59.75B BY 2025 AI REVENUE TO BALLOON

Market Intel firm, Tractica, concurs, predicting annual worldwide AI revenue to balloon from \$1.38 billion in 2016 to \$59.75 billion in 2025, A jump of \$58.37 billion in just nine years, or a compound annual growth rate of 52%.



Veriluma. Patently different.

INTRODUCING A WORLD FIRST:

PATENTED PRESCRIPTIVE AI

Veriluma has developed and patented an advanced algorithmic approach to deliver decisive insight to decision makers in real time. Enabling organizations to build an objective model of a complex decision process, with or without data, enabling disparate elements to be synthezed in a single evaluation.

FILLS IN GAPS: KNOWN VS. UNKNOWN

The platform can deal with what is known and can consider what is not.



Veriluma software is ambivalent to quality or quantity of data and is ambivalent to objective or subjective inputs.

Veriluma. For industry decision makers.

"SO, THE DATA ANALYSIS IS IN...

BUT HOW DO I MAKE THE BEST DECISION?"

INVESTMENT

VC funding, evaluate merger
& acquisition, large
infrastructure projects

GOVERNMENT

crime, law enforcement,
security assessment,
counter terrorism

RISK

diverse data, insurance, banking and risk mitigation

SALES

marketing, product,
research, customer
lifecycle


"Veriluma offers a unique type of prescriptive analysis, one that tackles the difficult strategic end of the decision spectrum."

GARTNER

Veriluma use cases



RISK ASSESSMENT FOR LENDING



PROBLEM SOLVED.

ZERO net credit losses to date,
due to automated, real time
dynamic risk assessment.



M&A FOR CORPORATE ADVISORS

Determine likelihood of success or failure upon completion of a merger or acquisition.

PROBLEM SOLVED.

Ability to calculate, determine and predict 'good value' post merger of combined businesses.

Veriluma use cases



INVENTORY OPTIMISATION

ID critical parts to ensure correct inventory available to avoid production failure.

PROBLEM SOLVED.

Reduced working capital, reduced loss of production days and reduced obsolecence.



START UP VENTURE VALIDATION

Critical analysis to determine the likelihood of success or failure pre-investment in a technology venture.

PROBLEM SOLVED.

Incorporated as key sprint planning milestone into organisations of all sizes; from startups through to in-house corporate teams.

Veriluma 2018-2019 highlights so far

DEFENCE CONTRACT

Signed 3 year, \$1.97M contract to supply software to the Department of Defence with remit to transfrom data into value-added intelligence plus 2 year option to renew.

POTENTIATE ALLIANCE

Potentiate is Australia's largest private statistical analysis firm. Potentiate deployed Veriluma's technology to predict consumer purchase intention to 83% accuracy. The program is to be rolled out end 2019.

AVVA PARTNERSHIP

JV with global design firm Made In The Now to provide early insight into the likelihood of success for startup ideas. Launched July 2019 as part of a Queensland Govt initiative.

UK INVESTMENT

Establishment of Decision Point as the primary base of operations for the group's expansion into Europe and the USA.

Veriluma Advisory Board

TONY GUOGA

Entrepreneur

A former Member of the European Parliament for Lithuania, the founder of Crypto Tax and Legal and the Blockchain Centre in Vilnius, Lithuania.

HENRY CHEANG

CEO, Potentiate

Global entrepreneur, founder and CEO of potentiate and NED of Information Tools, Kapiche, ID Driver and Non Executive Chair for Livius and Veriglif.

MEGAN JAMES

CEO, Australian Data Centres

The first female CEO of
Australian Data Centres,
President of WIIC (Women In IT
and Communications), Deputy Chair
of the Board of the Breast Cancer
Network Australia and board
member of AIIA.

KARL SMITH

Thought Leader, UK

A technology thought leader with a track record for building new technology products and services from the ground up including Wipro Digital, Accenture EUX and Zoopla.

EUGENE DUBOSSARSKY

Founder, AlphaZetta

A leader in the data analytics field and founding partner of Australian AI Company, Advantage Data, and the Chief Innovation Officer at catastrophe risk management company, reask.earth,

Veriluma: the future is bright

GLOBAL PRESENCE

UK, USA, Australia - go to market ready

VERTICAL SOLUTIONS

Defence, banking, insurance, legal

COMPLEMENTARY TECHNOLOGY ACQUISITIONS

Extend the technology platform. Extend the client base.

PROFESSIONAL SERVICES

Extend services to include consulting in data analytics and machine learning

RESEARCH

A hub for bespoke projects

"What should we do?"

